This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

27/100

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

This article tells us how modern biotechnology and AI are redefining Alzheimer’s disease through early detection, advanced biomarkers, and innovative treatments like lecanemab. It highlights global impact, behavioral aspects, and the role of lifestyle and technology in improving outcomes. Genetic and molecular mutations lead to onset of AD. Mutations in APP, PSEN1, PSEN2, along with risk factor such as APOE ε4 that increase the production of amyloid-β₄₂ and impaired amyloid clearance that later form neurotoxic plaques. These process also influence tau pathology, synaptic failure and neurodegenerative characteristic of alzheimer disease. Biomarkers have played a crucial role in the pre determination of Alzheimer's disease and have used to make precautionary measures. Imaging and biomarkers have been found to enable prevention measures to be taken early, and treatment is done with ChEIs, memantine, and anti-amyloid antibodies such as lecanemab and donanemab. New treatments are aimed at amyloid, tau, and inflammation, and genes, and stem cell and non-pharmacological interventions. New biotechnologies like gene editing, stem cells, nanotech, and AI are helping scientists better understand and treat Alzheimer’s disease. These modern tools make it possible to find the disease early and give more effective, personalized treatments.

Key findings

Biomarkers have played a crucial role in the pre determination of Alzheimer's disease and have used to make precautionary measures.
Imaging and biomarkers have been found to enable prevention measures to be taken early, and treatment is done with ChEIs, memantine, and anti-amyloid antibodies such as lecanemab and donanemab.
New treatments are aimed at amyloid, tau, and inflammation, and genes, and stem cell and non-pharmacological interventions.
New biotechnologies like gene editing, stem cells, nanotech, and AI are helping scientists better understand and treat Alzheimer’s disease.
These modern tools make it possible to find the disease early and give more effective, personalized treatments.

Why it matters

This review describes how biomarkers and imaging can enable prevention measures to be taken early, and how treatment includes ChEIs, memantine, and anti-amyloid antibodies such as lecanemab and donanemab. It states that new biotechnologies like gene editing, stem cells, nanotech, and AI are helping scientists better understand and treat Alzheimer's disease, though it reports no new trial results.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 27/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 26 of the 96 points we could judge it on, which is 27 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of medical & health sciences review.)
Journal's citation record	0 / 4	Journal of medical & health sciences review.: journal h-index 4 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 3 year(s) since 2025
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Dr. Maria Malik holds only 4 work(s), too few to judge a track record — left out of this score
Institution's track record	0 / 3	COMSATS University Islamabad: institution h-index 359 (OpenAlex)
Multi-centre collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	26 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 96 points we could judge it on is 27 out of 100.
Total	27 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Lateef, U., Junaid, A., Saeed, K., Khalil, H., Tasaddiq, M., & Malik, D. M. (2025). REDEFINING ALZHEIMER’S DISEASE THROUGH MODERN BIOTECHNOLOGY; FROM MOLECULAR PATHOGENESIS TO INNOVATIVE THERAPEUTICS AND DIAGNOSTIC FRONTIERS. Journal of medical & health sciences review.. https://doi.org/10.65035/w1y9ey43

Vancouver

Lateef U, Junaid A, Saeed K, Khalil H, Tasaddiq M, Malik DM. REDEFINING ALZHEIMER’S DISEASE THROUGH MODERN BIOTECHNOLOGY; FROM MOLECULAR PATHOGENESIS TO INNOVATIVE THERAPEUTICS AND DIAGNOSTIC FRONTIERS. Journal of medical & health sciences review.. 2025. doi:10.65035/w1y9ey43.

BibTeX

@article{lateef2025-92541794,
  author  = {Lateef, Uswa and Junaid, Aroob and Saeed, Khansa and Khalil, Habiba and Tasaddiq, Musfira and Malik, Dr. Maria},
  title   = {{REDEFINING ALZHEIMER’S DISEASE THROUGH MODERN BIOTECHNOLOGY; FROM MOLECULAR PATHOGENESIS TO INNOVATIVE THERAPEUTICS AND DIAGNOSTIC FRONTIERS}},
  journal = {Journal of medical \& health sciences review.},
  year    = {2025},
  doi     = {10.65035/w1y9ey43},
  url     = {https://doi.org/10.65035/w1y9ey43}
}

Related studies in Treatments

Also in Treatments

166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →